NHS Tayside has now considered your request dated 15 July 2019.

NHS Tayside wishes to advise you that there are exemptions applicable to the information requested. Please refer to the exemptions section of this correspondence.

**Extract from Request**

“I have a Freedom of Information request that wonder if you could help me with

Question 1 – How many adult patients with Cutaneous Squamous Cell Carcinoma have you seen / treated (example Surgery, Radiotherapy, Chemotherapy or combinations of these) in the last 6 months?

Question 2 – How many adult patients with locally advanced (patients with Perineural invasion and local Lymphovascular or Bone involvement) or Metastatic Cutaneous Squamous Cell Carcinoma (patients with both local and distant Nodal involvement, as well as any other organ involvement) have you seen / treated (example Surgery, Radiotherapy, Chemotherapy or combinations of these) in the last 6 months?

Question 3 – Of these how many are not candidates for Curative surgery or Curative Radiation?

Question 4 – In the past 6 months, how many adult patients with locally advanced or metastatic Cutaneous Squamous Cell Carcinoma have you treated with the following:

<table>
<thead>
<tr>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complex surgery only (eg patients with significant comorbidities, large reconstructions or amputations leading to significant loss of function or disfigurement)</td>
</tr>
<tr>
<td>Surgery + Radiotherapy (adjuvant / neoadjuvant)</td>
</tr>
<tr>
<td>Radiotherapy</td>
</tr>
<tr>
<td>Chemotherapy** only</td>
</tr>
<tr>
<td>Chemotherapy** + Radiotherapy</td>
</tr>
<tr>
<td>Surgery + Chemotherapy** (adjuvant / neoadjuvant)</td>
</tr>
<tr>
<td>Other (Please state)</td>
</tr>
<tr>
<td>Palliative Care / Best Supportive Care</td>
</tr>
</tbody>
</table>

Question 5 – Are you participating in any clinical trials for Cutaneous Squamous Cell Carcinoma (CSCC)?

If yes, please state which?
*Example of factors to consider when deciding if locally advanced patients are suitable candidates for surgery: Disease recurrence after two or more surgical procedures and the treating clinicians expected that curative resection would be unlikely

CSCC in a anatomically challenging location where surgery would result in substantial complications or deformity or dysfunction significant local invasion that precludes complete resection

* Example of factors to consider when deciding if locally advanced patients are suitable candidates for radiation:

CSCC in a anatomically challenging location where radiation would be associated with unacceptable toxicity risk in context of the patients overall condition

Clinical judgement that tumour might not respond to RT

Factors / conditions contradicting for RT

Prior treatment with RT for CSCC, and further RT would exceed the threshold of acceptable cumulative does

** Chemotherapy such as Cisplatin, Doxorubicin, 5-Fluorouracil (5-FU), Capecitabine, Topotecan, Methotrexate or Etoposide"

Response

1. Information not held. NHS Tayside does not hold information surrounding the number of adult patients with Cutaneous Squamous Cell Carcinoma who have been seen/treated in the last 6 months in an easily identifiable format.

2. Information not held. NHS Tayside does not hold information surrounding the number of patients with locally advanced (patients with Perineural invasion and local Lymphovascular or Bone involvement) or Metastatic Cutaneous Squamous Cell Carcinoma who have been you seen/treated in the last 6 months in an easily identifiable format.

3. NHS Tayside does not hold this information in a readily identifiable format.

4. NHS Tayside does not hold this information in a readily identifiable format.

To provide the information requested for Qs 1-4 above would require a manual exercise to extract information from various databases to correlate the information to provide accurate figures.
This exercise would require the allocation of resources that the service does not have and to comply with your request would result in excessive cost to NHS Tayside.

5. There are currently no clinical trials being undertaken by NHS Tayside for Cutaneous Squamous Cell Carcinoma.


<table>
<thead>
<tr>
<th>Document Ref.</th>
<th>FOISA Exemption Applied</th>
<th>Justification</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGTFOISA6527</td>
<td>Section 17 – Information not held</td>
<td>• NHS Tayside does not hold the information in the format requested</td>
</tr>
<tr>
<td></td>
<td>Section 12 – Excessive cost of compliance</td>
<td>• To compile the requested information would require a manual exercise to extract information from various databases • Once this information had been extracted, verification and analysis of that information would have to be undertaken. There is no resource available to NHS Tayside to undertake this work.</td>
</tr>
</tbody>
</table>

Under section 20 (1) of the Act, if you are dissatisfied with the way NHS Tayside has dealt with your request, you have a right to request a review of our actions and decisions in relation to your request, and you have a right to appeal to the Scottish Information Commission.

A request for an internal review must be made in writing no later than forty working days from receipt of this response and sent to:

Head of Information Governance  
Maryfield House (South)  
30 Mains Loans  
Dundee  
DD4 7BT

Or by email to informationgovernance.tayside@nhs.net
If you are not content with the outcome of the internal review, you have the right to apply directly to the Scottish Information Commissioner for a decision. The Scottish Information Commissioner can be contacted at:

Scottish Information Commissioner
Kinburn Castle
Doubledykes Road
St Andrews, Fife
KY16 9DS

Or via the online appeal service: www.itstopublicknowledge.info/Appeal

If you have any queries about this correspondence, please contact:

Information Governance Team
Maryfield House
30 Mains Loan
Dundee
DD4 7BT

Telephone - 01382 424413
E-mail: informationgovernance.tayside@nhs.net

Information Governance
NHS Tayside
1 August 2019